Decoding complex disease through multiomics
)
Complex diseases are shaped by polygenic risk, regulatory variation, and molecular mechanisms that cannot be fully explained by single-omics approaches.
In this webinar, our expert speakers will discuss how multiomic Oxford Nanopore sequencing supports a deeper understanding of disease mechanisms, by integrating DNA, RNA, and epigenetic analysis — all on a single platform.
PLEASE NOTE: This webinar will be offered in two timezones. Please select your preferred option on the form below.
You will learn:
- How multiomic Oxford Nanopore sequencing brings together characterisation of DNA variants, RNA isoforms, and DNA and RNA modifications for more comprehensive disease research.
- How multiomic insights can support biomarker discovery and translational research into neurodegenerative conditions such as Alzheimer’s disease.
- How Oxford Nanopore is unlocking new possibilities in RNA and cDNA sequencing, with a new cDNA-PCR protocol generating longer, more complete reads and more accurate isoform resolution than legacy technologies.
Meet the speakers
)
Walaa Mohamed, Market Segment Manager - Complex Disease, Oxford Nanopore TechnologiesWalaa is the Complex Disease Segment Market Manager at Oxford Nanopore Technologies. She works on supporting the adoption of long-read sequencing for the study of complex diseases. She has been at Oxford Nanopore Technologies for four years, contributing to the advancement of genomics applications and translational research. Prior to joining Oxford Nanopore, she worked as an R&D scientist at G42 on the validation phase of the Emirati Genome Project, focusing on end-to-end workflow development and population-scale implementation.
)
Ashan Musafer , Senior Field Application Scientist , Oxford Nanopore TechnologiesAshan Musafer is a Senior Field Application Scientist at Oxford Nanopore Technologies with over a decade of expertise in translational genomics and epigenetics. He holds a Bachelor’s degree in Biomedical science from Monash University and a Master’s degree in Laboratory Medicine from the Royal Melbourne Institute of Technology (RMIT). Over the past 3 years at Oxford Nanopore, Ashan has focused on technical enablement while supporting the planning, implementation and execution of various genomic initiatives across the Gulf and Central Asian region.
)
Patrick Murphy, Market Segment Manager - Single Cell, Oxford Nanopore TechnologiesAt Oxford Nanopore Technologies, Patrick Murphy works on single cell and bulk transcriptomics applications of Oxford Nanopore sequencing. He focuses on helping researchers understand where Oxford Nanopore sequencing approaches can add value to their transcriptomics studies, including analysis of full-length RNA molecules, isoforms, splice variation, and fusion transcripts.
